How AI Search Is Recommending Peptide Suppliers: Monthly Trends

Executive Summary

Phoenix Pharmaceuticals leads the October 2026 benchmark with 35.0% valid recommendation coverage, 5.7 points ahead of Core Peptides at 29.3%. That gap widened from September's narrow 3.5-point margin, after compressing through the middle of the series. Phoenix Pharmaceuticals' coverage rose 16.4 points from 18.6% in September to 35.0% in October, a significant month-over-month increase and the brand's first upward movement in the series. Against the July baseline, the leader's position is down 3.3 points from 38.3%, a change within normal variation.

AminoVault was the strongest sustained upward mover against the baseline. Its coverage rose 6.9 points from 12.0% in July to 18.9% in October, a significant increase, and it added 7.8 points from 11.1% in September to 18.9% in October, also significant. Blue Sky Peptide extended a three-month upward streak, rising 6.3 points from 0.4% in July to 6.7% in October, a significant gain from a small base.

No brand registered a significant decline across the full baseline-to-current series. The sharpest downward movement in the month belonged to Peptides Source, which fell 0.6 points from 0.9% in September to 0.3% in October, a change within normal variation and a very small base. Peptide Tech rose from 0.0% to 0.3% coverage, its first valid recommendation in the series.

Across the four-month series, four of seven brands now sit at or above 18.9% valid recommendation coverage in October: Phoenix Pharmaceuticals, Core Peptides, Biotech Peptides, and AminoVault. The July-to-October path shows the leader regaining ground lost earlier in the series while AminoVault and Blue Sky Peptide built sustained gains against the baseline.

Each monthly run begins with 489 prompt-surface observations (329 unique questions) across the benchmark's defined AI/search surface universe, down from 530 prompt-surface observations (349 unique questions) in September 2026. Of the October total, 467 mentioned a tracked brand or competitor; 411 were relevant and 56 were irrelevant. The public metrics use the 297 qualified observations that survive both qualification stages, down from 350 in September 2026, against 274 in July 2026.

Key Findings

AI Response Inconsistency Alerts

Questions This Section Answers

• What factual inconsistencies did AI platforms produce about peptide suppliers this month?
• Which brands and claims were involved in the critical and high-severity conflicts?

The benchmark detected 14 critical and high-severity factual inconsistencies across four AI platforms: Copilot, ChatGPT, Gemini, and Perplexity. Ten concern Blue Sky Peptide, three concern Core Peptides, and one concerns Peptide Tech.

Blue Sky Peptide

A critical inconsistency concerns the company's operational status. When asked "Is Blue Sky peptide a reputable company?", Copilot stated the company "shut down in late 2024 after FDA warnings; no longer active," citing a Real Peptides safety analysis and a third-party review guide, while Perplexity stated it was a "real, long-running seller" with an "operating website," citing the company's own terms and conditions page and its Trustpilot listing. A company cannot be both shut down and still selling.

A second critical inconsistency on the same operational question set Copilot ("shut down in late 2024; no longer active") against ChatGPT, which described the company as "an established operation, plausibly legitimate," citing the company's About Us page and its Trustpilot reviews. A third set Copilot against Gemini, which stated the company has been "operating since 2013, still active," citing Muscle and Brawn, Eroids, and Trustpilot listings.

A critical inconsistency surfaced on the question "Is blue sky peptide legal to buy?" ChatGPT stated the company "currently sells its products as 'research use only'" and is listed "Under Review" in the APRA vendor registry, while Copilot stated the company "shut down in late 2024 after FDA enforcement actions and is defunct."

Two further critical inconsistencies concerned the question "What is blue sky peptide?" Copilot stated the company shut down in late 2024 after FDA warnings, while ChatGPT described a vendor that "currently sells research peptides online" and Gemini described "an online supplier." Each answer cited the company's own product pages or third-party review sites.

A critical inconsistency on the question "Are blue sky peptides legitimate?" set ChatGPT ("a real, operating research-peptide vendor with a currently listed catalog") against Copilot ("shut down in late 2024 after FDA warnings, not a trustworthy source today").

Two high-severity factual conflicts concern the company's Trustpilot rating. On "Is Blue Sky peptide a reputable company?", ChatGPT reported "about 4.7/5 from 90 reviews" while Perplexity reported a "2.7/5 'Poor' rating," both citing the same Trustpilot review page. A separate conflict set Copilot's "4.8/5" against Perplexity's "2.7/5." The same listing cannot hold both ratings.

One high-severity conflict concerns third-party testing. On "What is blue sky peptide?", Copilot stated the company "did not consistently provide third-party testing or detailed quality assurance documentation," citing a Real Peptides safety analysis and a vendor review guide, while Gemini stated the company "provides Certificates of Analysis (COAs) from third-party testing," citing the company's own site. The same vendor cannot both consistently and inconsistently provide testing documentation.

Core Peptides

A high-severity inconsistency concerns average purity. On "Are core peptides trustworthy?", Gemini stated independent tracking platforms "averaging high purity metrics around 99%+," citing PeptideScores and a vendor review, while Copilot stated "independent HPLC/Mass Spec testing shows average purity around 96–97%, slightly below their 99% marketing claim," citing a comparison review and Know Your Peptide. These purity ranges do not overlap.

A high-severity inconsistency concerns COA availability. On "Is Core Peptides a legit company?", ChatGPT stated the company "doesn't consistently provide easily independently verifiable, batch-specific COAs" and that one independent database had insufficient COA data to assign a trust grade, while Copilot stated the company "provides batch-specific COAs, which is a strong sign of transparency," citing Real Peptides and Know Your Peptide. The cited Disclosed Labs page states it has "indexed 0 Certificate(s) of Analysis for Core Peptides."

A high-severity inconsistency concerns independent lab verification. On the same question, ChatGPT stated quality claims "are not independently established" and that no trust grade could be assigned, while Copilot cited "independent lab testing by accredited labs (Janoshik Analytical, MZ Biolabs)" confirming purity averaging 96–99%, with a "Finnrick rating of 9.4/10." The existence of independent verification cannot be both affirmed and denied.

Peptide Tech

A high-severity inconsistency concerns the company's testing record. On "Is Peptide Tech legit?", ChatGPT reported that "one independent investigation reported 11 tests with 7 passing and 4 failing," citing a Finnrick vendor report, while Copilot stated Disclosed Labs "gave Peptide Tech a Grade B (82/100) based on 221 COAs, with 220 passing and only 1 failing," citing a Disclosed Labs vendor page. A pass/fail record of 4 failures in 11 tests and 1 failure in 221 certificates are incompatible counts.

Benchmark Context

Questions This Section Answers

• How did the qualified benchmark set change between July and October 2026?
• What is the difference between the raw collection universe and the qualified analysis set?

The report separates the raw collection universe from the qualified analysis set. Brand-level recommendation percentages are calculated within the qualified benchmark set.

Benchmark-Level Metrics

The table below summarizes category-wide totals for the baseline-to-current comparison, separate from the individual brand figures that follow.

The intermediate months help interpret the path. Recommendation-shaped answer share moved from 47.1% in July to 47.6% in August, dipped to 27.1% in September, then recovered to 51.2% in October. Valid recommendation shortlist share followed a similar arc, from 52.2% to 38.9% to 31.7% to 66.0%. The October figures mark a return to the higher levels seen at the start of the series, against a smaller qualified observation set than September's.

AI Recommendation Trend

Questions This Section Answers

• Who leads the October 2026 peptide supplier benchmark, and how wide is the gap to second place?
• Which brands registered significant movement against the July baseline?

Leader's Edge Widens After a Narrow September

Phoenix Pharmaceuticals holds the top position in October 2026, and the gap to second place widened after narrowing through the middle of the series. The leader's 35.0% coverage sits 5.7 points above Core Peptides at 29.3% and 16.1 points above AminoVault at 18.9%. The top two brands now clear the mid-tier by a wider margin than in September.

Two brands exceeded normal month-to-month variation against the baseline: AminoVault and Blue Sky Peptide, both significant risers. The category-level change from July to October came from the combination of these gains against small declines in the leader and Biotech Peptides, rather than any single dominant movement.

What Changed This Month

Questions This Section Answers

• How did Phoenix Pharmaceuticals reverse its pattern and regain recommendation coverage in October?
• Which brands built sustained gains, and what distinguished their October positions?

Phoenix Pharmaceuticals: Leader Regains Ground in a Single Month

Phoenix Pharmaceuticals rose 16.4 points from 18.6% in September to 35.0% in October, a significant month-over-month increase and the brand's first upward movement in the series. Against the baseline, coverage is down 3.3 points from 38.3% in July, a change within normal variation.

Raw presence declined 9.0 points from 60.2% in July to 51.2% in October, the only supporting metric moving downward across the series. Top-three rate rose 5.6 points to 28.6% and rank-one rate rose 4.5 points to 12.5%, both changes within normal variation. The brand holds 104 valid recommendations of 297 observations and 37 rank-one placements.

The distinction the reader should notice is that Phoenix Pharmaceuticals lost presence and gained recommendation share across the series. Fewer answers mention the brand, but a larger share of those that do place it inside the recommendation set. Presence and recommendation continue to move in opposite directions.

Highest-priority diagnostic: Which prompts now return the brand as a top-three recommendation that did not in September, and whether the October recovery holds against a smaller qualified observation set.

AminoVault: Two-Month Surge to Fourth Place

AminoVault rose 6.9 points from 12.0% in July to 18.9% in October, a significant increase, and gained 7.8 points from 11.1% in September to 18.9% in October, also significant. This is the sharpest single-month move in the category this month and lifts the brand to fourth place.

Raw presence rose 7.8 points from 12.4% in July to 20.2% in October. Top-three rate rose 8.5 points to 16.2%, while rank-one rate rose 1.6 points to 7.4%, a change within normal variation. The brand holds 56 valid recommendations of 297 observations with 22 rank-one placements.

The distinction here is that AminoVault's October position is built on both presence and placement, not on one signal alone. The brand is named more often and placed higher within the answers that name it, reversing the September retracement.

Highest-priority diagnostic: Whether the September-to-October gain reflects a durable shift in which prompts surface the brand, or a single-month movement against a qualified set that fell from 350 to 297 observations.

Blue Sky Peptide: Three-Month Upward Streak

Blue Sky Peptide rose 6.3 points from 0.4% in July to 6.7% in October, a significant increase, and has moved upward in each of the last three months. The October month-over-month change of 1.3 points was within normal variation. The brand holds 20 valid recommendations of 297 observations, up from 19 of 350 in September.

Raw presence rose 7.7 points from 1.1% in July to 8.8% in October. Top-three rate rose 0.6 points to 1.0% and rank-one rate fell 0.4 points to 0.0%, both within normal variation. The brand's valid recommendation count (20) is higher than Peptide Tech's and Peptides Source's, even though its coverage rate remains among the lowest in the category, because it is named often without being placed near the top.

Because absolute counts are small, percentage movements should be read against the underlying numbers: 26 of 297 October observations mention the brand, and 3 sit inside a top-three shortlist.

Highest-priority diagnostic: Which prompt themes continue to lift the brand into answers, and why its presence converts to mid-ranking rather than top-three placement.

Biotech Peptides: Baseline Decline Masked by a Two-Month Recovery

Biotech Peptides fell 2.8 points from 22.3% in July to 19.5% in October, a change within normal variation, but rose 6.4 points from 13.1% in September to 19.5% in October, a significant increase. The baseline figure hides two successive monthly gains.

Raw presence fell 3.8 points from 32.1% to 28.3%, within normal variation, while rank-one rate fell 6.6 points from 10.6% to 4.0%. Top-three rate fell 4.3 points to 12.1%, within normal variation. The brand holds 58 valid recommendations of 297 observations with 12 rank-one placements. Net sentiment held at 0.8.

The distinction is that Biotech Peptides recovered recommendation coverage without recovering its leading-position share. The brand is inside the recommendation set more often than in September, but at a lower rank within it than in July.

Highest-priority diagnostic: Which prompts once returned the brand as the first recommendation and now place it lower, and which competitor holds the leading position in those answers.

Core Peptides: Second Place Held on Steady Coverage

Core Peptides rose 1.2 points from 28.1% in July to 29.3% in October, a change within normal variation, but gained 14.2 points from 15.1% in September to 29.3% in October, a significant increase, its second consecutive monthly gain.

Raw presence rose 1.0 point to 36.4% and top-three rate rose 3.6 points to 22.9%, both within normal variation. Rank-one rate rose 0.3 points to 6.1%. The brand holds 87 valid recommendations of 297 observations, with 18 rank-one placements. Net sentiment softened from 0.9 to 0.8.

The brand sits 5.7 points behind the leader, closer than any other tracked brand, and its October level matches its July baseline. The two-month recovery has returned Core Peptides to the position from which the series began.

Highest-priority diagnostic: Whether the September-to-October gain holds, given that the July-to-August and August-to-September movements were both sharp reversals.

Peptide Tech and Peptides Source: Very Small Bases

Peptide Tech rose 0.3 points from 0.0% in July to 0.3% in October, a change within normal variation. Its 1 valid recommendation of 297 observations is the brand's first in the series. Raw presence is 1.0% and net sentiment fell from 1.0 to 0.3. Any percentage movement here reflects a single observation and should be read as such.

Peptides Source fell 0.8 points from 1.1% in July to 0.3% in October, a change within normal variation, with 1 valid recommendation of 297 observations. Raw presence rose 0.2 points to 2.4%. Net sentiment fell from 0.5 to 0.1. With 7 of 297 observations mentioning the brand and 1 inside a recommendation set, percentage movements carry wide uncertainty.

Highest-priority diagnostic: For both brands, what would move them from occasional presence to consistent inclusion in recommendation answers, and whether their current counts reflect genuine standing or sparse coverage.

Notable Gap: AminoVault and Phoenix Pharmaceuticals

The benchmark flags a narrowing gap between AminoVault and Phoenix Pharmaceuticals, from 26.3 points in July to 16.1 points in October, a net narrowing of 10.2 points across the series, though not in every month. The narrowing reflects AminoVault's gains and Phoenix Pharmaceuticals' smaller baseline decline. Presented as a category observation: the distance between the leader and the fourth-place brand has contracted even as the leader's position over second place widened.

Highest-priority diagnostic: Whether the two brands now surface against the same prompt set, or whether they win different kinds of questions.

Buyer-Intent Interpretation

Questions This Section Answers

• Which buyer-intent clusters did October's qualified observations cover?
• What commercial questions can the current benchmark answer about peptide supplier recommendations?

All 297 qualified October observations fell into the Brand Recommendation class. Both the Pricing & Value and Multi-Brand Comparison classes contained zero observations, meaning the public benchmark cannot answer commercial questions about price positioning, value perception, or head-to-head comparison dynamics.

The buyer-intent mix remains centered entirely on direct recommendation queries. The October data speaks to which brands win when a buyer asks for a supplier recommendation, not to how brands fare when buyers weigh pricing or compare suppliers side by side. Those questions would require research beyond the current benchmark scope.

Brand Opportunity Summary

Questions This Section Answers

• Which brands show the strongest signal in the October benchmark, and what diagnostic question does each face?
• What distinguishes a brand with a durable position from one whose movement may not hold?

The benchmark identifies where attention is warranted; a company-level analysis is needed to explain why.

Evidence Behind the Benchmark

The aggregate metrics are built from prompt-level observations covering the query, the AI surface, the recommendation outcome, rank, sentiment, and citations where exposed. Company-level analysis can go deeper into prompt, competitor, surface, and evidence patterns. Source presence is not automatically treated as proof of causation.

About This Benchmark

This report is part of the CiteWorks Studio AI Visibility Industry Market research program.

• AI Visibility Industry Market Benchmark
• AI Visibility Industry Market Methodology
• AI Visibility Industry Market Metrics
• AI Visibility Industry Market Standards

Report-Specific Interpretation Notes

• Small counts warrant caution. Peptide Tech holds 1 valid recommendation of 297 October observations, Peptides Source holds 1, and Blue Sky Peptide holds 20, so percentage movements for these brands can appear large relative to a small base.
• The qualified denominator moved from 274 observations in July to 297 in October, after peaking at 350 in September. Comparisons are made between the qualified sets, not the raw collections, and the October set is smaller than September's.
• Directional analysis identifies changes worth investigating; it does not by itself establish the cause of those changes. The October recovery in recommendation-shaped answers reflects movement beneath the aggregate rates that prompt-level inspection can illuminate.

Next Step

The Public Benchmark Shows Where a Brand Is Winning or Losing. A Company-Level Audit Shows Why.

The aggregate percentages in this report raise questions that sit beneath the surface: which high-intent prompts are won, which competitor takes the recommendation when a brand loses, what attributes AI associates with each option, and which external sources shape those answers. For a category where the leader regained 16.4 points in a single month and two brands built sustained gains, the prompt-level detail matters as much as the headline rate.

A company-specific AI visibility audit maps those prompt, surface, competitor, ranking, sentiment, and evidence-source patterns into a prioritized visibility strategy. It moves from what changed to why it changed, and from category-wide movement to brand-specific diagnosis.

Request an AI visibility audit